PMID: 8951685Jan 1, 1996Paper

Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
T TaniguchiY Kitazawa

Abstract

This study was performed to clarify the ocular hypotensive mechanism of topical isopropyl unoprostone (unoprostone), a novel prostaglandin (PG) metabolite-related drug, in the rabbit eye. The intraperitoneal administration of indomethacin (50 mg/kg) 1 hour before administration of topical 0.12% unoprostone partially diminished the intraocular pressure (IOP) reduction, and completely blocked the increase in aqueous PGE2 concentration caused by unoprostone. Aqueous humor dynamics measurements in the unoprostone- and the vehicle-treated contralateral eyes with indomethacin pretreatment revealed that aqueous flow determined by fluorophotometry was not significantly different, 2.3 +/- 0.3 and 2.4 +/- 0.2 microliters/min, respectively; the total outflow facility measurements determined by the two-level constant pressure perfusion method were 0.20 +/- 0.01 and 0.14 +/- 0.01 microliters/min/mmHg, respectively (p < 0.05); the uveoscleral outflow measurements determined by the fluorescein isothiocyanate-dextran perfusion method were 0.49 +/- 0.02 and 0.46 +/- 0.02 microliters/min, respectively (p < 0.05). The magnitude of the IOP reduction induced by unoprostone was estimated to be 5.2 mmHg, which agrees well with the actual IOP reductio...Continue Reading

Citations

Dec 10, 2002·American Journal of Ophthalmology·Henry D JampelUNKNOWN Latanoprost/Unoprostone Study Group
Jul 23, 2003·Experimental Eye Research·Renyi WuIvan O Haefliger
Sep 3, 2002·Survey of Ophthalmology·Philip F J Hoyng, Yoshi Kitazawa
Sep 3, 2002·Survey of Ophthalmology·Kirk M MaxeyJennifer LaBrecque
Oct 25, 2003·Progress in Retinal and Eye Research·Vital P CostaLuis Metzner Serra
Jan 5, 2002·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Y TamakiA Tomidokoro
Sep 12, 2002·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·N A SharifJ Y Crider
Oct 30, 2003·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Naj A SharifAta A Abdel-Latif
Jan 22, 2004·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·N A SharifS X Xu
Jan 15, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Kirk N GelattAlison Biken
Aug 17, 2006·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Masahiko ShimuraKenji Kashiwagi
Nov 2, 2006·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Najam A SharifJanet L Parker
Mar 22, 2008·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Najam A SharifAta A Abdel-Latif
Mar 24, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Robert FaulknerDavid Dahlin
Nov 25, 2006·The British Journal of Ophthalmology·Takashi OtaMakoto Araie
Jan 22, 2002·The British Journal of Ophthalmology·Tin AungSteve K L Seah
Apr 26, 2003·The British Journal of Ophthalmology·A HommerUNKNOWN Unoprostone Adjunctive Therapy Study Group
Mar 25, 2008·Therapeutics and Clinical Risk Management·Robert J Noecker
Apr 3, 2001·Expert Opinion on Investigational Drugs·C Lindén
Jun 24, 2006·The Kaohsiung Journal of Medical Sciences·Chang-Lin ChenKwou-Yeung Wu
Feb 1, 1997·Survey of Ophthalmology·T YamamotoK Masuda
Aug 4, 2004·Ophthalmology·Bernard E McCareyUNKNOWN Unoprostone Monotherapy Study Group
Oct 9, 2001·American Journal of Ophthalmology·M SaitoS Shirato
Apr 14, 2016·Ophthalmic Genetics·Lance P Doucette, Michael A Walter
Feb 1, 2002·Journal of Glaucoma·Kenji KashiwagiShigeo Tsukahara
Aug 29, 2018·American Journal of Veterinary Research·Sangwan ParkKangmoon Seo
Mar 15, 2005·Current Eye Research·Hirokazu MukunoGail Seigel
Apr 25, 2000·Drugs·P F Hoyng, L M van Beek
Mar 15, 2006·International Ophthalmology·John S CohenLinda J Greff

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.